SLS

Business Context and Reporting Period

Company: SELLAS Life Sciences Group, Inc. (SLS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: A late-stage clinical biopharmaceutical company developing novel cancer therapeutics. Key product candidates include galinpepimut-S (GPS), a WT1-targeting immunotherapy, and SLS009 (tambiciclib), a CDK9 inhibitor. The company has no product sales revenue and relies on equity financing and licensing agreements.

Key Financial Metrics

Liquidity: As of September 30, 2025, the company held $44.3 million in cash and cash equivalents. Management expects this, combined with proceeds from a subsequent October 2025 warrant inducement ($29.1 million), to fund operations for at least 12 months.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by $4.6 million (18.6%) for the nine months ended September 30, 2025, compared to the prior year. This was driven primarily by a $2.6 million decrease in external clinical trial expenses and a $0.7 million decrease in manufacturing costs, largely due to the completion of enrollment in the REGAL Phase 3 study in Q1 2024.
• Net Loss Improvement: The net loss narrowed by $4.9 million for the nine-month period, reflecting lower operating costs and higher interest income ($0.8 million vs. $0.5 million).
• Capital Structure: Significant equity activity occurred in the first nine months of 2025, including a registered direct offering and warrant inducements, resulting in a net increase in cash of $30.4 million. Outstanding common shares increased from 74.0 million (Dec 31, 2024) to 125.1 million (Sep 30, 2025).

Outlook, Risks, and Management Commentary

• Clinical Progress:
  • GPS (REGAL Study): The Phase 3 study in AML maintenance has reached the interim analysis threshold (60 events). The Independent Data Monitoring Committee (IDMC) recommended continuing the study without modification. Final analysis is event-driven (80 events) and anticipated later in 2025.
  • SLS009: The Phase 2a trial in relapsed/refractory AML met all primary endpoints with an overall response rate of 33%. The FDA has recommended advancing to a first-line therapy trial, expected to begin enrollment in Q1 2026.
• Legal Proceedings: The company is engaged in binding arbitration against 3D Medicines Inc. regarding the trigger and payment of milestone payments (up to $13.0 million) and failure to use commercially reasonable efforts to develop GPS in Greater China. The outcome remains uncertain.
• Going Concern: While the company currently has sufficient liquidity for 12 months, it has an accumulated deficit of $267.3 million and expects to continue generating operating losses. Future funding will likely require additional equity or debt financing, which may be dilutive.
• Regulatory: GPS and SLS009 have received various Orphan Drug Designations (ODD) and Fast Track designations from the FDA and EMA. SLS009 also received Rare Pediatric Disease (RPD) designation.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $44.3 million cash balance plus the $29.1 million October 2025 inducement proceeds against the projected burn rate for the upcoming 12 months.
• REGAL Study Timeline: Monitor the timing of the final analysis (80 events) for the GPS Phase 3 trial, as this is the primary catalyst for a potential Biologics License Application (BLA).
• Arbitration Outcome: Track the status of the arbitration against 3D Medicines, as a favorable outcome could provide significant non-dilutive capital ($13M+ milestones).
• Dilution Risk: Review the impact of outstanding warrants (63.7 million shares) and options (2.7 million shares) on future share count and earnings per share.
• SLS009 First-Line Trial: Confirm the initiation of the FDA-recommended first-line AML trial in Q1 2026 and the enrollment progress.